Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)
A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.
100 项与 River Vision Development Corp. 相关的临床结果
0 项与 River Vision Development Corp. 相关的专利(医药)
100 项与 River Vision Development Corp. 相关的药物交易
100 项与 River Vision Development Corp. 相关的转化医学